Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18237
Country/Region: Tanzania
Year: 2018
Main Partner: Deloitte Consulting Limited
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $14,100,000 Additional Pipeline Funding: $2,053,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,140,594
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $760,395
Care: Pediatric Care and Support (PDCS) $126,734
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,267,325
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,426,756
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $8,617,801
Treatment: Pediatric Treatment (PDTX) $760,395
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 498
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 485
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 257
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 89
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 667
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 669
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 454
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 107
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 356
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 109
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 21
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 20
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 3,763
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 1,148
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 3,157
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 965
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 3,589
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 1,019
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 2,216
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 773
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 2,738
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 605
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 432
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 175
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 1,369
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 18,572
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 6,163
GEND_GBV Number of people receiving post-GBV care 2019 24,735
HTS_TST <5, Unknown Sex, Negative 2019 2,447
HTS_TST 15-19, Female, Negative 2019 175
HTS_TST 15-19, Male, Negative 2019 151
HTS_TST 20-24, Female, Negative 2019 489
HTS_TST 20-24, Male, Negative 2019 488
HTS_TST 25-29, Female, Negative 2019 2,794
HTS_TST 25-29, Female, Negative 2019 1,289
HTS_TST 25-29, Female, Negative 2019 16,260
HTS_TST 25-29, Female, Negative 2019 22,405
HTS_TST 25-29, Female, Negative 2019 842
HTS_TST 25-29, Female, Negative 2019 1,768
HTS_TST 25-29, Male, Negative 2019 2,334
HTS_TST 25-29, Male, Negative 2019 966
HTS_TST 25-29, Male, Negative 2019 11,990
HTS_TST 25-29, Male, Negative 2019 726
HTS_TST 25-29, Male, Negative 2019 1,270
HTS_TST 30-34, Female, Negative 2019 3,906
HTS_TST 30-34, Female, Negative 2019 1,758
HTS_TST 30-34, Female, Negative 2019 21,892
HTS_TST 30-34, Female, Negative 2019 22,405
HTS_TST 30-34, Female, Negative 2019 1,199
HTS_TST 30-34, Female, Negative 2019 2,467
HTS_TST 30-34, Male, Negative 2019 3,041
HTS_TST 30-34, Male, Negative 2019 1,176
HTS_TST 30-34, Male, Negative 2019 15,622
HTS_TST 30-34, Male, Negative 2019 926
HTS_TST 30-34, Male, Negative 2019 1,530
HTS_TST 35-39, Female, Negative 2019 5,316
HTS_TST 35-39, Female, Negative 2019 2,131
HTS_TST 35-39, Female, Negative 2019 29,432
HTS_TST 35-39, Female, Negative 2019 22,405
HTS_TST 35-39, Female, Negative 2019 1,631
HTS_TST 35-39, Female, Negative 2019 3,134
HTS_TST 35-39, Male, Negative 2019 3,790
HTS_TST 35-39, Male, Negative 2019 1,475
HTS_TST 35-39, Male, Negative 2019 20,104
HTS_TST 35-39, Male, Negative 2019 1,162
HTS_TST 35-39, Male, Negative 2019 1,895
HTS_TST 40-49, Female, Negative 2019 7,246
HTS_TST 40-49, Female, Negative 2019 2,875
HTS_TST 40-49, Female, Negative 2019 38,027
HTS_TST 40-49, Female, Negative 2019 33,607
HTS_TST 40-49, Female, Negative 2019 2,224
HTS_TST 40-49, Female, Negative 2019 4,070
HTS_TST 40-49, Male, Negative 2019 5,769
HTS_TST 40-49, Male, Negative 2019 2,450
HTS_TST 40-49, Male, Negative 2019 30,170
HTS_TST 40-49, Male, Negative 2019 1,841
HTS_TST 40-49, Male, Negative 2019 3,309
HTS_TST 50+, Female, Negative 2019 1,447
HTS_TST 50+, Male, Negative 2019 1,225
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 833,604
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 279
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 28,447
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 10,177
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 2,231
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 24,033
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 3,746
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 3,956
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 582
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 579
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 1,671
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,541
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 4,739
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 4,020
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 1,562
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 15,387
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 2,149
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 2,422
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 230
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 204
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 678
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 741
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 1,983
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 1,483
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 128,953
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 23,045
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 23,087
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 3,418
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 3,285
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 9,053
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 8,100
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 25,927
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 22,310
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 49,352
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 307
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 3,449
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 545
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 633
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 320
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 258
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 933
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 1,051
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 2,719
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 2,129
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 10,820
HTS_TST_POS <5, Unknown Sex, Positive 2019 6
HTS_TST_POS 15-19, Female, Positive 2019 12
HTS_TST_POS 15-19, Male, Positive 2019 30
HTS_TST_POS 20-24, Female, Positive 2019 23
HTS_TST_POS 20-24, Male, Positive 2019 43
HTS_TST_POS 25-29, Female, Positive 2019 295
HTS_TST_POS 25-29, Female, Positive 2019 40
HTS_TST_POS 25-29, Female, Positive 2019 869
HTS_TST_POS 25-29, Female, Positive 2019 845
HTS_TST_POS 25-29, Female, Positive 2019 28
HTS_TST_POS 25-29, Female, Positive 2019 73
HTS_TST_POS 25-29, Male, Positive 2019 252
HTS_TST_POS 25-29, Male, Positive 2019 47
HTS_TST_POS 25-29, Male, Positive 2019 737
HTS_TST_POS 25-29, Male, Positive 2019 65
HTS_TST_POS 25-29, Male, Positive 2019 39
HTS_TST_POS 30-34, Female, Positive 2019 421
HTS_TST_POS 30-34, Female, Positive 2019 59
HTS_TST_POS 30-34, Female, Positive 2019 1,175
HTS_TST_POS 30-34, Female, Positive 2019 845
HTS_TST_POS 30-34, Female, Positive 2019 52
HTS_TST_POS 30-34, Female, Positive 2019 93
HTS_TST_POS 30-34, Male, Positive 2019 319
HTS_TST_POS 30-34, Male, Positive 2019 48
HTS_TST_POS 30-34, Male, Positive 2019 908
HTS_TST_POS 30-34, Male, Positive 2019 35
HTS_TST_POS 30-34, Male, Positive 2019 46
HTS_TST_POS 35-39, Female, Positive 2019 581
HTS_TST_POS 35-39, Female, Positive 2019 91
HTS_TST_POS 35-39, Female, Positive 2019 1,680
HTS_TST_POS 35-39, Female, Positive 2019 845
HTS_TST_POS 35-39, Female, Positive 2019 32
HTS_TST_POS 35-39, Female, Positive 2019 129
HTS_TST_POS 35-39, Male, Positive 2019 413
HTS_TST_POS 35-39, Male, Positive 2019 69
HTS_TST_POS 35-39, Male, Positive 2019 1,225
HTS_TST_POS 35-39, Male, Positive 2019 3
HTS_TST_POS 35-39, Male, Positive 2019 71
HTS_TST_POS 40-49, Female, Positive 2019 799
HTS_TST_POS 40-49, Female, Positive 2019 133
HTS_TST_POS 40-49, Female, Positive 2019 2,246
HTS_TST_POS 40-49, Female, Positive 2019 1,257
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 170
HTS_TST_POS 40-49, Male, Positive 2019 664
HTS_TST_POS 40-49, Male, Positive 2019 126
HTS_TST_POS 40-49, Male, Positive 2019 1,869
HTS_TST_POS 40-49, Male, Positive 2019 11
HTS_TST_POS 40-49, Male, Positive 2019 158
HTS_TST_POS 50+, Female, Positive 2019 9
HTS_TST_POS 50+, Male, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 389
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 227
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 57
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 749
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 98
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 102
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 52
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 55
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 170
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 160
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 522
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 434
HTS_TST_POS Service Delivery Point (Facility) Inpatient: <1, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 256
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 39
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 77
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 71
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 235
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 2,644
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 405
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 400
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 166
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 182
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 521
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 531
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 1,488
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 1,348
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 102
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 104
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 28
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 108
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 99
PMTCT_ART Already on ART at beginning of current pregnancy 2019 4,152
PMTCT_ART New on ART 2019 4,573
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 8,725
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 148,858
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 6,984
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 1,734
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 8,718
PMTCT_EID Sum of Infant Age disaggregates 2019 8,718
PMTCT_STAT 25-29, Female 2019 37,246
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 1,170
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 34,924
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 1,114
PMTCT_STAT 30-34, Female 2019 29,776
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 918
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 27,929
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 882
PMTCT_STAT 35-39, Female 2019 22,333
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 675
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 20,949
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 642
PMTCT_STAT 40-49, Female 2019 4,471
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 70
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 4,203
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 68
PMTCT_STAT By Age (Numerator): 10-14 2019 1,487
PMTCT_STAT By Age (Numerator): 15-19 2019 7,442
PMTCT_STAT By Age (Numerator): 20-24 2019 44,661
PMTCT_STAT By Age (Numerator): 50+ 2019 1,487
PMTCT_STAT By Number of known positives: 10-14 2019 5
PMTCT_STAT By Number of known positives: 15-19 2019 163
PMTCT_STAT By Number of known positives: 20-24 2019 1,414
PMTCT_STAT By Number of known positives: 50+ 2019 5
PMTCT_STAT By Number of new negative: 10-14 2019 1,398
PMTCT_STAT By Number of new negative: 15-19 2019 6,988
PMTCT_STAT By Number of new negative: 20-24 2019 41,911
PMTCT_STAT By Number of new negative: 50+ 2019 1,398
PMTCT_STAT By Number of new positives: 10-14 2019 8
PMTCT_STAT By Number of new positives: 15-19 2019 144
PMTCT_STAT By Number of new positives: 20-24 2019 1,330
PMTCT_STAT By Number of new positives: 50+ 2019 8
PMTCT_STAT Number of new ANC and L&D clients 2019 156,691
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 148,858
PMTCT_STAT_den 25-29, Female 2019 39,184
PMTCT_STAT_den 30-34, Female 2019 31,325
PMTCT_STAT_den 35-39, Female 2019 23,498
PMTCT_STAT_den 40-49, Female 2019 4,708
PMTCT_STAT_den By Age (Denominator): <15-19 2019 7,831
PMTCT_STAT_den By Age (Denominator): 10-14 2019 1,568
PMTCT_STAT_den By Age (Denominator): 20-24 2019 47,009
PMTCT_STAT_den By Age (Denominator): 50+ 2019 1,568
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 937
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 20,192
TB_PREV By Age/Sex (Numerator): <15, Female 2019 937
TB_PREV By Age/Sex (Numerator): <15, Male 2019 2,484
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 20,192
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 17,493
TB_PREV IPT, Life-long ART, Already, Positive 2019 2,484
TB_PREV IPT, Life-long ART, New, Positive 2019 17,493
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 41,151
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 48,410
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 1,026
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 4,333
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 24,259
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 18,731
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 779
TB_PREV_den IPT, Life-long ART, New, Positive 2019 47,594
TX_CURR 25-29, Female, Positive 2019 18,966
TX_CURR 25-29, Male, Positive 2019 5,636
TX_CURR 30-34, Female, Positive 2019 24,191
TX_CURR 30-34, Male, Positive 2019 9,229
TX_CURR 35-39, Female, Positive 2019 23,975
TX_CURR 35-39, Male, Positive 2019 10,957
TX_CURR 40-49, Female, Positive 2019 30,578
TX_CURR 40-49, Male, Positive 2019 17,160
TX_CURR Age/Sex: <1 2019 619
TX_CURR Age/Sex: <1-9 2019 9,520
TX_CURR Age/Sex: 10-14 Female 2019 3,017
TX_CURR Age/Sex: 10-14 Male 2019 3,208
TX_CURR Age/Sex: 15-19 Female 2019 2,761
TX_CURR Age/Sex: 15-19 Male 2019 1,931
TX_CURR Age/Sex: 20-24 Female 2019 5,844
TX_CURR Age/Sex: 20-24 Male 2019 2,410
TX_CURR Age/Sex: 50+ Female 2019 23,911
TX_CURR Age/Sex: 50+ Male 2019 16,446
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 210,467
TX_CURR Sum of age/sex disaggregates 2019 4,692
TX_NEW 25-29, Female, Positive 2019 2,112
TX_NEW 25-29, Male, Positive 2019 1,893
TX_NEW 30-34, Female, Positive 2019 2,902
TX_NEW 30-34, Male, Positive 2019 2,184
TX_NEW 35-39, Female, Positive 2019 3,844
TX_NEW 35-39, Male, Positive 2019 2,734
TX_NEW 40-49, Female, Positive 2019 5,283
TX_NEW 40-49, Male, Positive 2019 4,412
TX_NEW Breastfeeding status 2019 624
TX_NEW By Age/Sex: <1 2019 383
TX_NEW By Age/Sex: 1-9 2019 4,103
TX_NEW By Age/Sex: 10-14 Female 2019 607
TX_NEW By Age/Sex: 10-14 Male 2019 655
TX_NEW By Age/Sex: 15-19 Female 2019 431
TX_NEW By Age/Sex: 15-19 Male 2019 415
TX_NEW By Age/Sex: 20-24 Female 2019 1,233
TX_NEW By Age/Sex: 20-24 Male 2019 1,344
TX_NEW By Age/Sex: 50+ Female 2019 3,458
TX_NEW By Age/Sex: 50+ Male 2019 2,862
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 41,325
TX_NEW Pregnancy status 2019 5,652
TX_NEW Sum of Age/Sex disaggregates 2019 11,005
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 203,284
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 2,923
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 5,564
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 133,073
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 61,714
TX_PVLS_den Denominator: Indication: Routine 2019 203,284
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,944
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 800
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 28,312
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 14,183
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 45,283
TX_RET Numerator by Status: Breastfeeding 2019 476
TX_RET Numerator by Status: Pregnant 2019 5,722
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 50,305
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,174
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 893
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 31,424
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 15,758
TX_RET_den Denominator by Status: Breastfeeding 2019 542
TX_RET_den Denominator by Status: Pregnant 2019 6,356
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 173,084
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 5,018
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 5,179
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 112,296
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 50,618
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 1,134
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,134
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 141,465
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 1,177
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 30,157
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 226
Cross Cutting Budget Categories and Known Amounts Total: $517,264
Gender: Gender Based Violence (GBV) $8,632
Post GBV Care
Implementation
Capacity building
Gender: Gender Equality $500,000
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Human Resources for Health $8,632